share_log

CustomerInsights.AI Recognized in the Gartner Hype Cycle for Life Science Commercial Operations, 2024 for the 2nd Time in a Row

CustomerInsights.AI Recognized in the Gartner Hype Cycle for Life Science Commercial Operations, 2024 for the 2nd Time in a Row

CustomerInsights.人工智能再次入選2024年加特納生命科學商業運營曲線炒作週期。
PR Newswire ·  09/11 21:00

SCOTTSDALE, Ariz., Sept. 11, 2024 /PRNewswire/ -- CustomerInsights.AI has once again been recognized in the Gartner Hype Cycle for Life Science Commercial Operations, 2024. This marks the second consecutive year CustomerInsights.AI has been included in the Data and Analytics (D&A) Platforms in Commercial Life Sciences category. We believe, this recognition underscores our commitment to pioneering advancements in technology and innovation within the life sciences industry.

亞利桑那州斯科茨代爾,2024年9月11日 /PRNewswire/ — CustomerInsights.AI 在 2024 年 Gartner 生命科學商業運營炒作週期中再次獲得認可。這標誌着 CustomerInsights.AI 連續第二年被列入 「商業生命科學數據與分析 (D&A) 平台」 類別。我們相信,這一認可凸顯了我們對生命科學行業在技術和創新方面開創性進步的承諾。

According to Gartner, "Life science organizations (LSOs) — encompassing pharmaceutical, biotechnology and medical device sectors — are undergoing transformative shifts to achieve top enterprise goals of operational efficiency, business growth and regulatory compliance (see Life Science 2024 CIO Agenda Insights and Data).". In our opinion, this recognition reflects our dedication to driving innovation and excellence in the life sciences industry. We look forward to continuing to lead the way in transforming commercial operations through cutting-edge technology.

根據Gartner的說法,「生命科學組織(LSO)——包括製藥、生物技術和醫療器械領域——正在進行變革性轉變,以實現運營效率、業務增長和監管合規等企業首要目標(參見生命科學 2024 年首席信息官議程見解和數據)。」我們認爲,這一認可反映了我們致力於推動生命科學行業的創新和卓越。我們期待通過尖端技術繼續引領商業運營轉型。

Abhay Jajoo, CEO of CustomerInsights.AI, says "We are once again proud to have been recognized in the Gartner Hype Cycle for Life Science Commercial Operations, 2024, which we think reaffirms the impact of our platform-led approach at CIAI. ciPARTHENON continues to deliver significant business value for our Life Sciences customers, helping them achieve faster results at lower costs. We believe this mention for 2024 underscores our commitment to innovation that truly matters - advancing technological maturity and driving business outcomes. We remain dedicated to pushing the boundaries of what's possible."

CustomerInsights.AI 首席執行官Abhay Jajoo表示:「我們再次爲在2024年Gartner生命科學商業運營炒作週期中獲得認可感到自豪,我們認爲這再次證實了我們在CIAI平台主導的方法的影響。Ciparthenon繼續爲我們的生命科學客戶創造可觀的商業價值,幫助他們以更低的成本更快地取得成果。我們認爲,此次提及2024年的舉措凸顯了我們對真正重要的創新的承諾——提高技術成熟度和推動業務成果。我們仍然致力於突破可能性的界限。」

As noted by Gartner, "Commercial D&A platforms streamline data management processes with robust industry- specific capabilities for data ingestion, data quality tracking and data governance on a prebuilt commercial operations data model. These platforms give business users and data scientists more control by enabling data access through advanced capabilities (such as an interactive information portal, an analytical workbench and a data science laboratory)."

正如Gartner指出的那樣,「商業數據分析平台通過強大的行業特定功能簡化了數據管理流程,可在預建的商業運營數據模型上進行數據提取、數據質量跟蹤和數據治理。這些平台允許通過高級功能(例如交互式信息門戶、分析工作臺和數據科學實驗室)訪問數據,從而爲業務用戶和數據科學家提供了更多的控制權。」

Our Commercial Analytics Cloud – ciPARTHENON helps integrate key Marketing & Customer Engagement applications such as Omnichannel management, Social & GenAI Intelligence, and Next Best Action. This integration delivers a cohesive and intelligent customer experience, enabling organizations to effectively manage and enhance their customer relationships.

我們的商業分析雲——Ciparthenon幫助整合關鍵的營銷和客戶互動應用程序,例如全渠道管理、社交和GenAI情報以及下一步最佳行動。這種集成提供了緊密而智能的客戶體驗,使組織能夠有效地管理和增強其客戶關係。

CustomerInsights.AI's advanced integration of generative AI (GenAI) and analytics has set new standards for operational efficiency and customer engagement. Our technologies are pivotal in driving personalization, optimizing market access, improving patient engagement, and leveraging data analytics. These areas reflect the evolving needs of Life Science Organizations(LSOs) to adapt to new challenges and opportunities.

CustomerInsights.AI 對生成式人工智能 (GenAI) 和分析的高級集成爲運營效率和客戶參與度設定了新的標準。我們的技術在推動個性化、優化市場準入、提高患者參與度和利用數據分析方面至關重要。這些領域反映了生命科學組織(LSO)不斷變化的需求,以適應新的挑戰和機遇。

For more details on how ciPARTHENON Cloud can elevate your data and analytics capabilities, visit Customerinsights.ai or reach out to us directly.

有關 Ciparthenon Cloud 如何提升您的數據和分析能力的更多詳細信息,請訪問 Customerinsights.ai 或直接聯繫我們。

Source: Gartner, Hype Cycle for Life Science Commercial Operations, 2024, Animesh Gandhi, 13 August 2024

來源:Gartner,《生命科學商業運營的炒作週期》,2024 年,Animesh Gandhi,2024 年 8 月 13 日

GARTNER is a registered trademark and service mark of Gartner and Hype Cycle are a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

GARTNER 是 Gartner 的註冊商標和服務標誌,Hype Cycle 是 Gartner, Inc. 和/或其關聯公司在美國和國際上的註冊商標,經許可在此使用。版權所有。

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not recommend that technology users select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner 不認可其研究出版物中描述的任何供應商、產品或服務,也不建議技術用戶只選擇評級最高或其他稱號的供應商。Gartner 研究出版物由 Gartner 研究機構的觀點組成,不應被解釋爲事實陳述。Gartner 不對本研究做出任何明示或暗示的擔保,包括對適銷性或特定用途適用性的任何擔保。

About CustomerInsights.AI:
For more information about ciPARTHENON and its comprehensive suite of solutions for life sciences, please visit

關於 CustomerInsights.AI:
有關 Ciparthenon 及其全套生命科學解決方案的更多信息,請訪問

SOURCE CustomerInsights.AI

來源 CustomerInsights.AI

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想在 PRNEWSWIRE.COM 上刊登貴公司的新聞嗎?

440k+
440k+

Newsrooms &
新聞編輯室和

Influencers
有影響力的人
9k+
9k+

Digital Media
數字媒體

Outlets
網點
270k+
270k+

Journalists
記者

Opted In
選擇加入
GET STARTED
開始吧

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論